Health & Fitness
Health and Fitness
Health and Fitness 
Thu, July 29, 2010
Wed, July 28, 2010
Targacept to Report Second Quarter 2010 Financial Results on August 4, 2010
WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the second quarter ended June 30, 2010 on Wednesday, August 4, 2010, after the U.S. financial markets close.
Management will discuss the second quarter results, provide an update on the companya™s product development programs and business activities and discuss expectations for the future via conference call at 5:00 p.m. Eastern Daylight Time on Wednesday, August 4, 2010. The conference call may be accessed by dialing (800) 591-6942 for domestic participants and (617) 614-4909 for international callers (reference passcode 93542084). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Daylight Time on August 4, 2010 through August 18, 2010 by dialing (888) 286-8010 for domestic callers and (617) 801-6888 for international callers (reference passcode 99843216).
A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacepta™s website, [ www.targacept.com ]. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacepta™s website for at least two weeks following the call.
About Targacept
Targacept is developing a diverse pipeline of innovative NNR Therapeuticsa" for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacepta™s lead program, TC-5214, is in Phase 3 development as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentada" to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. Targacept is committed to Building Health and Restoring Independencea" for patients. For more information, please visit [ www.targacept.com ].